Dr. Paul T. Kotzbauer's lab focuses on understanding how protein aggregation impacts cognitive decline in Parkinson's disease. They investigate how the buildup of certain proteins in the brain, like alpha-synuclein, contributes to dementia and other cognitive deficits in patients with Parkinson's. By analyzing brain tissue from autopsy samples, the lab aims to uncover the relationship between these protein accumulations, neuronal degeneration, and cognitive functioning in patients.

Dr. Paul J Shaw's lab focuses on understanding how sleep disruption and Alzheimer's disease (AD) are interconnected. They study the brain's molecular mechanisms that play a role in both conditions using innovative techniques in humans and fruit flies. By analyzing gene expression patterns, they aim to identify potential targets for new treatments that could help improve sleep and reduce the risk of Alzheimer's disease.

Dr. Chihiro Sato's lab at Washington University focuses on understanding primary tauopathies, a group of brain disorders that include conditions like progressive supranuclear palsy and frontotemporal degeneration. The lab is investigating specific forms of tau proteins in cerebrospinal fluid that could serve as biomarkers to assist in the diagnosis and treatment of these diseases. By identifying changes in tau proteoforms during disease progression, their work aims to improve clinical trials and personalize medicine for patients suffering from these disorders.

Dr. Ganesh M Babulal's lab focuses on understanding the risk factors for Alzheimer’s disease, particularly in African American populations. The research aims to identify how environmental, social, and psychological factors contribute to cognitive decline and the risk of Alzheimer’s. This is achieved by collaborating with community members and involving participants in comprehensive assessments over several years to gather vital data that can influence future treatments and interventions.

Dr. Erik Musiek's lab at Washington University focuses on understanding how disruptions in circadian rhythms affect brain function and contribute to Alzheimer's Disease. The lab explores the role of specific proteins, called REV-ERBs, in regulating the activity of astrocytes, which are support cells in the brain. By manipulating these proteins, the goal is to find new therapeutic strategies to mitigate the damaging effects of Alzheimer's Disease on brain health.

Dr. David Gutmann's lab focuses on understanding neurofibromatosis type 1 (NF1) and its impact on brain tumors and neurodevelopmental problems in children. They aim to uncover the biological mechanisms behind NF1-related conditions to improve treatment strategies and patient outcomes. The lab utilizes integrative approaches, combining patient-derived cells, advanced genetic techniques, and mouse models to explore how different cell types interact in these diseases.